KYGEVVI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kygevvi, and what generic alternatives are available?
Kygevvi is a drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in KYGEVVI is doxecitine; doxribtimine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the doxecitine; doxribtimine profile page.
DrugPatentWatch® Generic Entry Outlook for Kygevvi
Kygevvi will be eligible for patent challenges on November 3, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 3, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for KYGEVVI?
- What are the global sales for KYGEVVI?
- What is Average Wholesale Price for KYGEVVI?
Summary for KYGEVVI
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in KYGEVVI? | KYGEVVI excipients list |
| DailyMed Link: | KYGEVVI at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for KYGEVVI
Generic Entry Date for KYGEVVI*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
FOR SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for KYGEVVI
KYGEVVI is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of KYGEVVI is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | 11,649,259 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | 10,471,087 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ucb Inc | KYGEVVI | doxecitine; doxribtimine | FOR SOLUTION;ORAL | 219792-001 | Nov 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for KYGEVVI
See the table below for patents covering KYGEVVI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2016280293 | ⤷ Start Trial | |
| Australia | 2020204042 | ⤷ Start Trial | |
| Australia | 2021250841 | ⤷ Start Trial | |
| Brazil | 112017027079 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for KYGEVVI
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3310362 | C20265012 | Finland | ⤷ Start Trial | |
| 3310362 | 301385 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DOXECITINE EN DOXRIBTIMINE; REGISTRATION NO/DATE: EU/1/25/2013 20260327 |
| 3310362 | CR 2026 00027 | Denmark | ⤷ Start Trial | PRODUCT NAME: DOXECITIN OG DOXRIBTIMIN; REG. NO/DATE: EU/1/25/2013 20260327 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch